[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"chronic-coronary-syndrome\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:chronic-coronary-syndrome":28},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,42,0,25,[9,46,74,102,128,159,187,210,237,263,299,326,353,381,412,434,458,486,510,535,555,577,604,634,654],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":16,"eligibilityCriteria":17,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":29,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100642022","comparison-of-the-incidence-of-major-cardiovascular-events-between-the-combination-of-percutaneous-intervention-and-optimal-drug-therapy-and-the-optimal-drug-therapy-alone-in-patients-with-chronic-coronary-syndrome-100642022",false,"NCT07577518","Comparison of the Incidence of Major Cardiovascular Events Between the Combination of Percutaneous Intervention and Optimal Drug Therapy and the Optimal Drug Therapy Alone in Patients With Chronic Coronary Syndrome","Percutaneous Intervention Versus Optimal Medical Therapy in Chronic Coronary Syndrome (PIVOT) Trial","PIVOT","Inclusion Criteria:\n\n* Patients aged 40 years or older\n* Patients suspected of having chronic coronary syndrome who have undergone coronary angiography and confirmed stenotic lesions\n* Patients with lesions suitable for stent insertion who have 50% or more visually estimated stenosis in major coronary arteries with a diameter of 2.5 mm or greater observed on coronary angiography, and who satisfy one or more of the following conditions:\n\n  1. Patients with stenosis of 70% or more confirmed via Quantitative coronary angiography (50% or more for the left main coronary artery)\n  2. Minimum lumen area (MLA) ≤ 4 mm² or plaque burden \\>70% on intravascular ultrasound (IVUS)\n  3. MLA \\\u003C3.5 mm² or area stenosis (AS) \\>65% on Optical Coherence Tomography (OCT)\n  4. The corresponding stenosis on localizing stress imaging using SPECT or PET When there is a significant focal ischemic deficit in the coronary artery region of the lesion and the total perfusion deficit (TPD) is ≥10%\n  5. Pressure wire-based fractional flow reserve (FFR) ≤0.80\n* Patients who can verbally confirm their understanding of invasive physiological or imaging evaluations and the benefits, harms, and alternative treatments of coronary angioplasty using drug-eluting stents, and for whom the patient or their legal representative can submit a written consent form.\n\nAdditional Criteria for nested RCT Studies\n\n* When heart rate control is deemed therapeutically important due to an accompanying increase in heart rate at rest or during symptomatic episodes.\n* When the use of beta-blockers is deemed clinically advantageous due to a history of myocardial infarction.\n* When beta-blockers can help control blood pressure and symptoms in cases of concomitant hypertension.\n* When there is a clinical situation requiring associated tachyarrhythmia or heart rate control.\n* When beta-blockers are deemed more appropriate due to a history of contraindications, intolerance, or side effects of calcium channel blockers.\n\nExclusion Criteria:\n\n* Patients with Left Ventricular Ejection Fraction (LVEF) less than 35%\n* Patients with cardiogenic shock\n* Patients with pulmonary edema or heart failure unresponsive to standard treatment\n* Patients with unstable angina whose symptoms persist despite maximal drug therapy\n* Patients with a history of ST-segment elevation myocardial infarction (STEMI), non-ST-segment elevation myocardial infarction (NSTEMI), or unstable angina within the last 6 months\n* Patients with active bleeding\n* Patients with major bleeding of the gastrointestinal or urinary system within the last 3 months\n* Patients with coagulation disorders prone to bleeding (including heparin-induced thrombocytopenia)\n* Patients with hypersensitivity to or contraindications to the following drugs: Heparin, Aspirin, Clopidogrel, Prasugrel, Contrast media (Patients sensitive to contrast media are not excluded if the condition can be effectively prevented through pretreatment with steroids or diphenhydramine (e.g., flare-ups).\n* Patients for whom percutaneous coronary intervention (PCI) is contraindicated\n* Patients who have already undergone coronary artery bypass grafting (CABG)\n* Patients with in-stent restenosis in the target lesion\n* Patients with chronic total occlusion (CTO) in major coronary arteries\n* Patients with lesions having an FFR of less than 0.64\n* Patients with coronary arteries that are anatomically unsuitable for both PCI and CABG\n* Patients with non-ischemic dilated cardiomyopathy or hypertrophic cardiomyopathy\n* Patients with severe valvular disease or those judged by the investigator to be likely to require valve surgery or percutaneous valve replacement during the study period\n* Patients with non-cardiac diseases, etc., with a life expectancy of less than one year or expected to have low treatment adherence (at the investigator's judgment)\n* Pregnant or breastfeeding patients\n* Other patients deemed by the investigator to be unsuitable for participation in the clinical trial\n\nAdditional Criteria for nested RCT Studies\n\n* Significant bradycardia at rest, second-degree or higher atrioventricular block, or significant conduction disturbance\n* Bronchial asthma or clinically significant bronchospasmodic disease\n* Symptomatic hypotension\n* Variant angina as a main presentation\n* Other cases where the supervising investigator deems the use of beta-blockers medically inappropriate","ALL","40 Years",{"count":21,"type":22},2301,"ESTIMATED","INTERVENTIONAL",[25],"NA","Comparison of the incidence of major cardiovascular events between the combination of percutaneous intervention and optimal drug therapy and the optimal drug therapy alone in patients with chronic coronary syndrome.\n\n* Main RCT (Randomized Clinical Trial): Patients with chronic coronary syndrome enrolled in the study will be randomized in a 1:1 ratio to either 1) PCI(Percutaneous Coronary Intervention) plus optimal medical therapy or 2) optimal medical therapy alone, with clinical outcomes assessed during follow-up. (2,301 participants)\n* Nested RCT: An embedded randomized supplementary study was conducted on a subset (220 participants) of the total subjects.\n\nIn patients who have decided to use beta-blockers for the control of angina, additional 1:1 randomization evaluates the efficacy of carvedilol sustained-release (SR) and immediate-release (IR) formulations. Both formulations are targeted for use up to the maximal tolerated dose, taking into account patient symptoms.",[28],"Chronic Coronary Syndrome",[30,31,32],"chronic coronary syndrome","percutaneous coronary intervention","optimal medical therapy","NOT_YET_RECRUITING","2026-06-10",{"date":36,"type":37},"2026-06-12","ACTUAL",{"date":39,"type":22},"2026-06-15",{"date":41,"type":22},"2034-03-10",{"name":43,"class":44},"Seoul National University Hospital","OTHER",20,{"id":47,"slug":48,"hasResults":12,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":4,"eligibilityCriteria":52,"healthyVolunteers":12,"sex":18,"minAge":53,"maxAge":4,"enrollmentInfo":54,"targetDuration":56,"studyType":57,"phases":4,"briefSummary":58,"conditions":59,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":4},"100642567","effects-of-icosapent-ethyl-on-coronary-plaque-inflammation-and-ventricular-remodeling-100642567","NCT07641257","Effects of Icosapent Ethyl on Coronary Plaque, Inflammation, and Ventricular Remodeling","Impact of Icosapent Ethyl on Ventricular Remodeling, Inflammation, and Coronary Plaque Stability in Patients With Acute or Chronic Coronary Syndrome: A Prospective, Observational, Real-World Study","Inclusion Criteria:\n\n* Age 18 years and older, of any sex.\n\n  * Definite diagnosis of chronic coronary syndrome (CCS) according to the Chinese Guidelines for the Diagnosis and Management of Patients with Chronic Coronary Syndrome, or acute coronary syndrome (ACS) according to the 2025 ACC\u002FAHA\u002FACEP\u002FNAEMSP\u002FSACI Guideline for the Management of Acute Coronary Syndromes.\n  * Laboratory evaluation showing fasting triglycerides (TG) \\>= 1.7 mmol\u002FL.\n  * Ability to fully understand the study purpose, voluntary participation, and provision of signed written informed consent.\n\nExclusion Criteria:\n\n* Women who are planning a pregnancy, currently pregnant, or lactating.\n\n  * Known hypersensitivity or allergic reaction to the active ingredient of icosapent ethyl (IPE) or any of its excipients (applicable to patients in the exposure cohort).\n  * Diagnosed with major life-threatening conditions such as malignant tumors, end-stage lung disease, or advanced neurodegenerative diseases, with a life expectancy of less than 12 months.\n  * Concurrent participation in any other interventional clinical trial involving investigational drugs or medical devices.\n  * Any other condition or severe non-compliance that, in the judgment of the investigator, makes the patient unsuitable for enrollment in this study.","18 Years",{"count":55,"type":22},420,"12 Months","OBSERVATIONAL","Even with standard treatments like statins, patients with coronary artery disease often face a residual risk of further heart events. This risk is largely driven by ongoing inflammation and unstable fatty plaques in the heart's blood vessels. Icosapent ethyl (IPE) is a highly purified prescription medication known to improve cardiovascular outcomes, but its detailed effects on the heart's structure and inflammation in everyday clinical practice need further exploration.\n\nThis study is a prospective, observational, real-world study designed to evaluate the effectiveness of IPE in patients with Acute Coronary Syndrome (ACS) or Chronic Coronary Syndrome (CCS). The study plans to enroll 420 patients who will be followed for 12 months. Based on their routine clinical prescriptions, participants will be grouped into a control group (receiving standard cardiovascular care, including statins) and an exposure group (receiving standard care plus IPE).\n\nThroughout the 1-year follow-up, researchers will conduct regular blood tests and advanced heart imaging. The main goal is to determine if adding IPE to standard therapy leads to a more significant reduction in inflammation. Additionally, the study will observe how IPE affects the stability of coronary plaques and the healing process of ventricular remodeling in a real-world clinical setting.",[60,28,61,62,63,64],"Acute Coronary Syndromes (ACS)","Coronary Artery Disease","Atherosclerosis Cardiovascular Disease","Ventricular Remodeling","Inflammation","2026-06-08",{"date":67,"type":37},"2026-06-11",{"date":69,"type":22},"2026-05-30",{"date":71,"type":22},"2029-05-30",{"name":73,"class":44},"Ruijin Hospital",{"id":75,"slug":76,"hasResults":12,"nctId":77,"briefTitle":78,"officialTitle":78,"acronym":79,"eligibilityCriteria":80,"healthyVolunteers":12,"sex":18,"minAge":53,"maxAge":4,"enrollmentInfo":81,"targetDuration":83,"studyType":57,"phases":4,"briefSummary":84,"conditions":85,"keywords":4,"overallStatus":91,"whyStopped":4,"lastUpdateSubmitDate":92,"lastUpdatePostDateStruct":93,"startDateStruct":95,"completionDateStruct":97,"leadSponsor":99,"locationsCount":101},"100615361","microplastics-and-nanoplastics-in-patients-with-chronic-coronary-syndromes-100615361","NCT07291609","Microplastics and Nanoplastics in Patients With Chronic Coronary Syndromes","CCS-Plastics","Inclusion Criteria:\n\nALL the following:\n\n1. Age \\> 18 years old;\n2. Suspected or known chronic coronary syndromes undergoing coronary CT angiography;\n3. Clinical indication to invasive coronary angiography;\n4. Able to give informed consent.\n\nExclusion Criteria:\n\n1. Coronary CT angiography not available;\n2. Poor quality CCTA;\n3. Absence of native coronary stenosis \\>=50% at CCTA;\n4. Contraindications to invasive coronary angiography and percutaneous coronary intervention\n5. Life expectancy \\\u003C 1 year due to non-cardiac pathology",{"count":82,"type":22},120,"3 Years","The CCS-plastics is an investigator-initiated, prospective, multicenter study of patients undergoing coronary CT angiography (CCTA) for suspected or known chronic coronary syndromes (CCS) referred to invasive coronary angiography for clinical indication. Patients identified as eligible for the protocol will be asked for written consent to participate in the study. The patients' dossiers will be uploaded and transmitted to the core laboratory for analysis. The routine management of the CCS patients will not be affected and all patients will be managed according to current standards. Invasive coronary angiography and coronary blood samples will be performed following the current standards, guidelines, and indications. During invasive coronary angiography, coronary blood samples will be collected per standard of care and sent to a centralized, specialized core laboratory for MNPs and biomarkers analysis. The central core lab for MNPs analyses will be the University of Campania Luigi Vanvitelli, Naples, Italy. The identification, quantification (concentration, mcg\u002Fml), and typing of plastic particles will be performed in each tube for each patient, using pyrolysis-gas chromatography-mass spectrometry (Py-GC\u002FMS) and laser direct infrared (LDIR) spectroscopy. The CCTA will be centrally analyzed by Centro Cardiologico Monzino to evaluate qualitative and quantitative plaque features. Patients will be followed clinically at 1 and 3 years per standard of care.",[28,86,87,61,88,89,90],"Microplastics","Nanoplastics","Coronary Plaque","Computed Tomography","Pollution Exposure","RECRUITING","2026-06-06",{"date":94,"type":37},"2026-06-09",{"date":96,"type":37},"2025-01-01",{"date":98,"type":22},"2029-12-31",{"name":100,"class":44},"Azienda Ospedaliera \"Sant'Andrea\"",6,{"id":103,"slug":104,"hasResults":12,"nctId":105,"briefTitle":106,"officialTitle":107,"acronym":4,"eligibilityCriteria":108,"healthyVolunteers":12,"sex":18,"minAge":53,"maxAge":4,"enrollmentInfo":109,"targetDuration":56,"studyType":57,"phases":4,"briefSummary":111,"conditions":112,"keywords":116,"overallStatus":91,"whyStopped":4,"lastUpdateSubmitDate":119,"lastUpdatePostDateStruct":120,"startDateStruct":121,"completionDateStruct":123,"leadSponsor":125,"locationsCount":127},"100643138","advanced-invasive-diagnosis-strategy-for-post-pci-patients-with-stable-coronary-syndromes-undergoing-coronary-angiography-100643138","NCT07638137","Advanced Invasive Diagnosis Strategy for Post-PCI Patients With Stable Coronary Syndromes Undergoing Coronary Angiography","Advanced Invasive Diagnosis Strategy for Post-PCI Patients With Stable Coronary Syndromes Undergoing Coronary Angiography: the AID Post-PCI Angina Study","Inclusion Criteria:\n\n* Patients with a history of previous percutaneous coronary intervention (PCI) with drug eluting stent (DES), bare metallic stent (BMS), or drug coated balloon (DCB) due to acute coronary syndrome or chronic coronary syndrome, who presented with angina or documented myocardial ischemia by non-invasive testing and are referred for invasive coronary angiography.\n\nExclusion Criteria:\n\n* Acute myocardial infarction (ST-segment elevation myocardial infarction \\[STEMI\\] and non-ST-segment elevation myocardial infarction \\[NSTEMI\\]).\n* Age \\\u003C 18 years old.\n* Pregnancy.\n* Severe left ventricle systolic dysfunction (left ventricular ejection fraction ≤30 %).\n* Congestive heart failure with reduced ejection fraction.\n* Concomitant severe valvular heart disease.\n* Severely decreased renal function (glomerular filtration rate \\\u003C 30 mL\u002Fmin\u002F1.73 m2).\n* Significant epicardial coronary artery disease unable to be treated by PCI.\n* Previous coronary artery bypass grafting (CABG).\n* Presence of any anatomic features precluding intracoronary instrumentation with pressure guidewires.\n* Contraindications to the administration of adenosine or acetylcholine.",{"count":110,"type":22},246,"AID Post-PCI Angina is as an observational, prospective, single-cohort, multicenter study designed to investigate the causes and origins of post-PCI angina by using the advance invasive diagnosis (AID) strategy combining with angiography derived physiology (ADP) in an all-comers population of patients with post-PCI angina referred for invasive coronary angiography. An all-comers population of patients with a history of previous percutaneous coronary intervention (PCI), who presented with angina or documented myocardial ischemia by non-invasive testing and are referred for invasive coronary angiography (ICA) will be enrolled. ICA will be performed with the application of the structure AID strategy to evaluate both obstructive and non-obstructive cause of myocardial ischemia. Then, angiography derived physiological assessment of epicardial coronary artery using functional coronary angiography in each vessel will be performed in both index procedure and the previous procedure in all patients. By combining information obtained from both procedures, the causes and origins of post-PCI angina will be made. Treatment will be decided by the operators according to the result. Patients will complete the Seattle Angina Questionnaire (SAQ) at baseline and at 1, 6, and 12 months after the procedure. The main hypothesis of this study states that, in patients with post-PCI angina referred to ICA, the application of the structured AID strategy combining with angiography derived physiology (ADP) will lead to a high diagnostic yield in identifying the origins of obstructive disease and causes of post-PCI angina.",[113,114,115,28],"Angina (Stable)","Percutaneous Coronary Intervention (PCI)","INOCA (Ischemia With Non Obstructive Coronary Artery Disease)",[117,118,28],"Angina","Percutaneous Coronary Intervention","2026-06-04",{"date":34,"type":37},{"date":122,"type":37},"2025-03-12",{"date":124,"type":22},"2028-03-30",{"name":126,"class":44},"Fundacion Investigacion Interhospitalaria Cardiovascular",5,{"id":129,"slug":130,"hasResults":12,"nctId":131,"briefTitle":132,"officialTitle":132,"acronym":133,"eligibilityCriteria":134,"healthyVolunteers":12,"sex":18,"minAge":53,"maxAge":4,"enrollmentInfo":135,"targetDuration":4,"studyType":23,"phases":137,"briefSummary":139,"conditions":140,"keywords":142,"overallStatus":91,"whyStopped":4,"lastUpdateSubmitDate":119,"lastUpdatePostDateStruct":150,"startDateStruct":152,"completionDateStruct":154,"leadSponsor":156,"locationsCount":158},"100607945","phase-3-comparing-high-and-low-dose-aspirin-with-dual-antiplatelet-therapy-for-three-months-using-prasugrel-and-aspirin-following-coronary-artery-bypass-grafting-optimus-cabg-trial-100607945","NCT07195149","Comparing High and lOw-dose asPirin With Dual anTIplatelet Therapy for Three Months Using prasUgrel and aSpirin Following Coronary Artery Bypass Grafting. (OPTIMUS-CABG Trial)","OPTIMUS-CABG","Inclusion Criteria:\n\nA. Baseline (preoperative) inclusion criteria\n\n1. Age \\>18 years\n2. Primary isolated CABG patients with stable coronary artery disease (chronic coronary syndrome) planned for at least 2 grafts. Coronary artery disease will be defined as a stenosis ≥ 70% based on coronary angiography, a FFR value ≤ 0.80 or iFr value ≤0.89; a left main diameter stenosis ≥ 50%, left main IVUS MLA value ≤ 6 mm2, or equivalent OCT measurements will also be considered.\n3. Ability to comply with all study procedures and follow-up procedures\n4. Signed Informed Consent to participate in the study.\n\nB. Operative inclusion criteria:\n\n1. Intraoperative graft evaluation using transit time flow measurement in all grafts, normal flow in any graft is defined as mean graft flow \\> 15 mL\u002Fmin with Pulsatility Index \\\u003C 5\n2. Left anterior descending artery grafted with internal thoracic artery\n3. No intraoperative decision for hybrid revascularization due to incomplete revascularization (Percutaneous coronary intervention (PCI) of the ungrafted vessel)\n4. No endarterectomy of the grafted vessel performed\n5. Patient did not have any additional unplanned procedure (Ex. LAAC, Ablation, valve intervention, aortic intervention)\n\nExclusion Criteria:\n\nA. Baseline (preoperative) exclusion criteria:\n\n1. Cardiogenic shock\n2. Patients with recent acute coronary syndrome (ACS) (\\\u003C12 months)\n3. Single vessel CABG\n4. Patients with preoperative atrial fibrillation\n5. Dialysis\n6. Thrombocytopenia (platelet count \\\u003C 100 000 platelets\u002FuL)\n7. Anemia (Hemoglobin level \\\u003C 10 g\u002FdL)\n8. Severe liver failure Child-Pugh classification \\>4\n9. Known, active infections with HIV, HBV, HCV, tuberculosis\n10. Active malignant disease or history of malignancy within the past 5 years\n11. Indication for DAPT (e.g. recent PCI or ACS or recent stents of peripheral arteries)\n12. Indication for oral anticoagulant treatment 13 Indications for the use of methotrexate at a dose of 15 mg\u002Fweek or more\n\n14\\. Any contraindication for prasugrel or ASA 15. Planned additional cardiac or non-cardiac surgery within 12 months 16. Non-cardiac co-morbidity with life expectancy less than 12 months 17. History of any bleeding complications due to the use of DAPT 18. History of intracranial bleeding 19. History of gastro-intestinal bleeding 20. Pregnancy or breastfeeding 21. Lack of compliance with the use of a highly effective method of birth control 22. Planned coronary endarterectomy 23. Severe impaired renal function (eGFR \\\u003C40mL\u002Fmin\u002F1.73 m2).\n\nB. Postoperative and prior randomization exclusion criteria:\n\n1. Perioperative cardiogenic shock\n2. Intraoperative death or death prior randomization\n3. Myocardial infarction within 12-24 hours following CABG or prior randomization\n4. Ischemic or hemorrhagic stroke within 12-24 hours following CABG or prior randomization\n5. Any postoperative complication that may increase patients' risk with DAPT\n6. Atrial Fibrillation prior randomization\n7. Gastro-intestinal bleeding prior randomization",{"count":136,"type":22},1703,[138],"PHASE3","The purpose of this study is to compare the effect of prasugrel plus low-dose aspirin versus high dose aspirin alone (300mg) and versus low dose aspirin alone (75 mg) in patients with chronic coronary disease undergoing coronary artery bypass grafting.",[28,141],"Stable Coronary Artery Disease CAD",[143,144,145,146,147,148,149],"DAPT","CABG","Prasugrel","Aspirin","CCS","Chronic coronary syndrome","Stable coronary artery disease",{"date":151,"type":37},"2026-06-05",{"date":153,"type":37},"2025-11-25",{"date":155,"type":22},"2030-11-30",{"name":157,"class":44},"Dolnośląskie Centrum Chorób Serca im.prof. Zbigniewa Religi MEDINET Sp. z o.o.",18,{"id":160,"slug":161,"hasResults":12,"nctId":162,"briefTitle":163,"officialTitle":163,"acronym":164,"eligibilityCriteria":165,"healthyVolunteers":12,"sex":18,"minAge":53,"maxAge":4,"enrollmentInfo":166,"targetDuration":168,"studyType":57,"phases":4,"briefSummary":169,"conditions":170,"keywords":174,"overallStatus":91,"whyStopped":4,"lastUpdateSubmitDate":180,"lastUpdatePostDateStruct":181,"startDateStruct":182,"completionDateStruct":184,"leadSponsor":186,"locationsCount":127},"100638082","derivation-and-validation-of-the-aortic-valve-echocardiographic-calcium-score-to-confirm-severe-aortic-stenosis-the-echo-avcs-study-100638082","NCT07620925","Derivation and Validation of the Aortic Valve Echocardiographic Calcium Score to Confirm Severe Aortic Stenosis: the Echo-AVCS Study","Echo-AVCS","Inclusion Criteria:\n\n* Age \\> 18 years old\n* Clinical indication for standard transthoracic echocardiography.\n* Clinical indication for cardiac CT with available calcium score.\n* 3-month time interval between transthoracic echocardiography and cardiac CT.\n* Able to give informed consent.\n\nExclusion Criteria:\n\n* Patients with inadequate transthoracic echocardiographic images.\n* Poor quality cardiac CT, inadequate for standard calcium score assessment.\n* Patients with known prior stents and\u002For coronary artery bypass grafts.\n* Patients with known previous percutaneous or surgical aortic valve replacement.\n* Patients with active or a history of endocarditis.\n* Patients with congenital heart defects (other than isolated bicuspid aortic valve).",{"count":167,"type":22},250,"1 Year","The Echo-AVCS Study is an investigator-initiated, prospective, multicenter observational study designed to derive and validate an artificial intelligence (AI)-based echocardiographic aortic valve calcium score (Echo-AVCS) for confirming severe aortic stenosis (AS). Transthoracic echocardiography (TTE) is the standard imaging modality for assessing AS severity; however, discrepancies between valve area and transvalvular gradient measurements may complicate diagnosis, particularly in low-flow or discordant AS presentations. Cardiac computed tomography (CT)-derived aortic valve calcium scoring is currently used to resolve diagnostic uncertainty, but it involves additional cost and radiation exposure. This study will enroll consecutive adult patients undergoing clinically indicated TTE and cardiac CT with calcium scoring performed within 3 months. Standardized echocardiographic images will be centrally analyzed using dedicated AI-based image segmentation and machine learning methods to quantify aortic valve calcification directly from TTE images. CT-derived aortic valve calcium score will serve as the reference standard. The primary objective is to derive and validate the Echo-AVCS score for identifying severe AS. Secondary objectives include determination of sex-specific diagnostic thresholds, correlation with CT calcium volume, association with symptoms and NYHA class, and evaluation of prognostic associations with aortic valve replacement, heart failure hospitalization, cardiovascular events, and mortality at 1-year follow-up.",[171,28,172,173],"Aortic Stenosis","Calcific Aortic Valve Disease","Calcific Aortic Stenosis",[175,176,177,178,179],"Aortic stenosis","Low-flow","Aortic valve calcium score","Echocardiography","Cardiac-CT","2026-06-03",{"date":119,"type":37},{"date":183,"type":37},"2026-03-01",{"date":185,"type":22},"2027-12-31",{"name":100,"class":44},{"id":188,"slug":189,"hasResults":12,"nctId":190,"briefTitle":191,"officialTitle":192,"acronym":4,"eligibilityCriteria":193,"healthyVolunteers":12,"sex":18,"minAge":53,"maxAge":194,"enrollmentInfo":195,"targetDuration":4,"studyType":23,"phases":196,"briefSummary":198,"conditions":199,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":200,"lastUpdatePostDateStruct":201,"startDateStruct":203,"completionDateStruct":205,"leadSponsor":207,"locationsCount":4},"100639741","phase-1-a-trial-to-compare-what-the-body-does-to-selatogrel-and-the-effect-of-selatogrel-in-chinese-adults-with-chronic-coronary-syndrome-100639741","NCT07615868","A Trial to Compare What the Body Does to Selatogrel and the Effect of Selatogrel in Chinese Adults With Chronic Coronary Syndrome","Randomized Trial to Assess the Pharmacokinetics, the Pharmacodynamics, and the Tolerability of a Single 16 mg Dose of Selatogrel (ACT-246475) in Chinese Adults With Chronic Coronary Syndrome","Key Inclusion Criteria:\n\n* Chronic coronary syndrome participants defined by the presence of any of the following conditions:\n\n  * History of coronary artery disease with coronary artery stenosis confirmed by a coronary catheterization (at any time prior to Screening) \u002F computed tomography (CT) angiogram ≥ 50%.\n  * Previously documented myocardial infarction occurring more than 3 months prior to Screening.\n* Acetylsalicylic acid as mono antiplatelet background therapy stable for at least 1 month prior to Screening.\n* Minimum weight of 50.0 kg at Screening.\n\nKey Exclusion Criteria:\n\n* Known liver impairment significantly affecting the hepatic function (e.g., ascites, icterus, signs of coagulopathy).\n* End-stage renal failure requiring dialysis.\n* Treatment with another investigational small-molecule or peptide drug within 3 months or 5 × t1\u002F2 (whichever is longer) or with an investigational antibody treatment within 6 months prior to Screening.\n* History of major medical or surgical disorders, which in the opinion of the investigator, are likely to interfere with the metabolism, or excretion of the trial treatment(s) (appendectomy and herniotomy allowed).\n* Concomitant diseases (e.g., advanced liver cirrhosis, mental illness, neurodegenerative disease, terminal malignancy, etc.) or conditions (e.g., inability to communicate well with the investigator in the local language, inability to consent) that, in the opinion of the investigator, may prevent subject from complying with study requirements or may be a confounder for the study interpretation.\n* Conditions associated with atherosclerosis:\n\n  * Acute coronary syndrome, percutaneous coronary intervention, Coronary Artery Bypass Grafting, or any intervention for peripheral artery disease within 3 months prior to randomization.\n  * Acute ischemic stroke or transient ischemic attack within 3 months prior to randomization\n* Mitigation of bleeding risks:\n\n  * Active internal bleeding, or medical history of recent (\\\u003C 1 month) bleeding disorders or conditions associated with high risk of bleeding (e.g., clotting disturbances, gastrointestinal bleed, hemoptysis, or any history of intracranial bleeding).\n  * Hemoglobin ≤ 10 g\u002FdL at Screening.\n  * Loss of at least 250 mL of blood within 3 months prior to Screening.","85 Years",{"count":45,"type":22},[197],"PHASE1","The purpose of this study is to evaluate the pharmacokinetics (PK), pharmacodynamics, and tolerability of a single dose of selatogrel in Chinese adults with chronic coronary syndrome.\n\nPharmacokinetics is the study of the absorption and breakdown of the study drug in the body. Pharmacodynamics is the study of the effect of the study drug on the body.\n\nResearchers will compare selatogrel to a placebo (a look-alike substance that contains no drug).\n\nParticipants will stay at the research clinic for 3 or 4 days (2 or 3 nights), during which time they will receive a single dose of selatogrel or placebo. A telephone call for post-trial safety follow-up will be done 30-40 days after the participant leaves the clinic.",[28],"2026-05-22",{"date":202,"type":37},"2026-05-29",{"date":204,"type":22},"2026-06",{"date":206,"type":22},"2026-10",{"name":208,"class":209},"Viatris Innovation GmbH","INDUSTRY",{"id":211,"slug":212,"hasResults":12,"nctId":213,"briefTitle":214,"officialTitle":215,"acronym":216,"eligibilityCriteria":217,"healthyVolunteers":12,"sex":18,"minAge":53,"maxAge":218,"enrollmentInfo":219,"targetDuration":4,"studyType":23,"phases":221,"briefSummary":222,"conditions":223,"keywords":227,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":229,"lastUpdatePostDateStruct":230,"startDateStruct":232,"completionDateStruct":233,"leadSponsor":235,"locationsCount":4},"100637529","computed-tomography-angiography-based-procedural-planning-in-percutaneous-coronary-intervention-100637529","NCT07592312","Computed Tomography Angiography Based Procedural Planning in PeRcutaneOus Coronary InterVEntion","CT-PROVE: Computed Tomography Angiography Based Procedural Planning in PeRcutaneOus Coronary InterVEntion","CT-PROVE","Inclusion Criteria:\n\n* Adults aged 18 to 80 years\n* Ability to provide written informed consent\n* Patients undergoing coronary computed tomography angiography (CCTA) for suspected coronary artery disease or for diagnostic work-up of stabilized acute coronary syndrome\n* Presence of at least one target coronary lesion meeting one of the following CCTA criteria:\n\n  * Severe coronary diameter stenosis (70-99%) in one or more coronary arteries according to CAD-RADS 4A or 4B classification and at least one of the following:\n  * CT-derived fractional flow reserve (CT-FFR) ≤0.80\n  * At least 2 high-risk plaque characteristics, including:\n  * Low attenuation plaque density \\\u003C30 Hounsfield units\n  * Positive remodeling index \\>1.1\n  * Napkin-ring sign\n  * Spotty calcification\n  * Left main coronary artery stenosis ≥50%\n  * Ostial or proximal left anterior descending artery, dominant left circumflex artery, or dominant right coronary artery stenosis ≥50% and at least one of the following:\n  * CT-FFR ≤0.80\n  * At least 2 high-risk plaque characteristics, including:\n  * Low attenuation plaque density \\\u003C30 Hounsfield units\n  * Positive remodeling index \\>1.1\n  * Napkin-ring sign\n  * Spotty calcification\n* Planned clinically indicated invasive coronary angiography with operator decision to proceed with PCI\n\nExclusion Criteria:\n\n* Contraindication to iodinated contrast media, including severe allergy or contrast-induced nephropathy\n* Poor-quality or non-diagnostic CCTA imaging\n* Target lesions involving in-stent restenosis\n* Chronic total occlusion target lesions\n* Operator decision to treat a vessel not identified as a target vessel by the CCTA core laboratory analysis\n* Pregnancy or breastfeeding\n* Patients referred for coronary artery bypass graft surgery after invasive coronary angiography\n* Participation in another investigational drug or drug-coated device study\n* Inability to provide informed consent","80 Years",{"count":220,"type":22},200,[25],"The goal of this clinical trial is to learn whether coronary CT angiography (CCTA)-guided planning improves the efficiency and outcomes of percutaneous coronary intervention (PCI) in adults with coronary artery disease. It will also evaluate the feasibility and safety of using a CT-based \"virtual PCI plan\" during coronary interventions.\n\nThe main questions it aims to answer are:\n\n* Does CCTA-guided PCI reduce procedural time, radiation exposure, and contrast dye use compared with standard PCI?\n* Does CCTA-guided PCI improve procedural outcomes and stent optimization?\n* How often do operators follow or deviate from the CT-based procedural plan?\n* What medical problems or complications occur during and after CCTA-guided PCI?\n\nResearchers will compare CCTA-guided PCI with standard angiography-guided PCI to determine whether CT-derived procedural planning improves PCI efficiency and clinical outcomes.\n\nParticipants will:\n\n* Undergo PCI guided either by a CCTA-based virtual planning strategy or by standard clinical practice\n* Attend follow-up assessments at 1 month, 6 months, and 1 year\n* Undergo routine clinical evaluations and imaging assessments related to their PCI procedure\n* Be monitored for procedural complications, symptoms, repeat procedures, and cardiovascular outcomes during follow-up\n\nThe study will also include a parallel observational registry for patients whose coronary lesions are deferred from PCI, to evaluate their long-term clinical outcomes.",[224,28,60,225,118,226],"Coronary Arteries Disease","Myocardial Ischemia","Coronary Computed Tomography Angiography",[61,228,118,226],"Chronic Coronary Disease","2026-05-13",{"date":231,"type":37},"2026-05-18",{"date":231,"type":22},{"date":234,"type":22},"2028-12-30",{"name":236,"class":44},"University of Galway",{"id":238,"slug":239,"hasResults":12,"nctId":240,"briefTitle":241,"officialTitle":242,"acronym":243,"eligibilityCriteria":244,"healthyVolunteers":12,"sex":18,"minAge":53,"maxAge":4,"enrollmentInfo":245,"targetDuration":4,"studyType":23,"phases":247,"briefSummary":248,"conditions":249,"keywords":250,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":254,"lastUpdatePostDateStruct":255,"startDateStruct":257,"completionDateStruct":259,"leadSponsor":261,"locationsCount":4},"100636981","phase-3-aspirin-versus-clopidogrel-in-chronic-coronary-syndrome-in-arabian-gulf-countries-100636981","NCT07572747","Aspirin Versus Clopidogrel in Chronic Coronary Syndrome in Arabian Gulf Countries","Aspirin Versus Clopidogrel for Secondary Prevention of Atherosclerotic Cardiovascular Events in Patients With Chronic Coronary Syndrome in the Arabian Gulf Countries: A Randomized, Open-label, Multi-Center Trial by the Gulf Trialists' Collaboration","ARCTURUS-GTC-1","Inclusion Criteria:\n\n1. Age ≥18 years.\n2. Significant coronary artery disease (coronary angiogram documentation of Left Main artery lesion ≥50% and\u002For lesion(s) ≥70% in other coronary arteries, and\u002For FFR\\\u003C0.8 or iFR\\\u003C0.9).\n3. Completed at least 6 months post ACS (regardless of the bleeding risk, anti-platelet strategy, revascularization strategy \"PCI, CABG, or conservative medical management only\", before randomization).\n4. Agreement to give written informed consent.\n\nExclusion Criteria:\n\n1. History of hypersensitivity to aspirin or clopidogrel.\n2. Presence of non-cardiac comorbidity with life expectancy ≤2 years from randomization.\n3. Plan for surgery or intervention which requires stopping antiplatelet agents ≥3 months.\n4. Females with childbearing potential or breast-feeding.\n5. Co-administration of contraindicated medications as follows: anticoagulants (warfarin, direct oral anticoagulants (DOACs), or chronic therapy of heparin); cytochrome P450 2C19 inhibitors (fluoxetine, moclobemid or voriconazole); probenecid; high dose of methotrexate (≥15 mg\u002Fweek); lithium.\n6. Inability to have a complete follow-up for up to 5 years from randomization (e.g: high possibility of travelling outside the country).\n7. Inability to afford paying for Clopidogrel out-of-pocket up to 5 years from randomization (in case not being covered by the health care system).",{"count":246,"type":22},6740,[138],"Determine the long-term efficacy of clopidogrel compared with aspirin in reducing heart or brain attacks in patients with stable heart disease",[28],[251,252,253],"aspirin","clopidogrel","Major Adverse Cardiovascular Events","2026-05-07",{"date":256,"type":37},"2026-05-11",{"date":258,"type":22},"2027-04-01",{"date":260,"type":22},"2032-04-01",{"name":262,"class":44},"Khalid F Alhabib",{"id":264,"slug":265,"hasResults":12,"nctId":266,"briefTitle":267,"officialTitle":268,"acronym":269,"eligibilityCriteria":270,"healthyVolunteers":12,"sex":18,"minAge":53,"maxAge":4,"enrollmentInfo":271,"targetDuration":4,"studyType":23,"phases":273,"briefSummary":274,"conditions":275,"keywords":283,"overallStatus":91,"whyStopped":4,"lastUpdateSubmitDate":290,"lastUpdatePostDateStruct":291,"startDateStruct":293,"completionDateStruct":295,"leadSponsor":297,"locationsCount":101},"100572699","orbital-atherectomy-vs-intravascular-lithotripsy-for-the-treatment-of-calcified-coronary-nodules-orbit-shock-100572699","NCT06736665","Orbital Atherectomy vs Intravascular Lithotripsy for the Treatment of Calcified Coronary Nodules (ORBIT-SHOCK).","Comparative Efficacy of Orbital Atherectomy and Intravascular Lithotripsy in the Treatment of Calcified Coronary Nodules. The ORBIT-SHOCK Pilot Study.","ORBIT-SHOCK","Inclusion Criteria:\n\n1. Patients aged ≥ 18 years.\n2. Atherosclerotic coronary artery disease with calcified nodules identified by OCT in a native vessel, eligible for percutaneous coronary revascularization.\n3. Clinical presentation of chronic coronary syndrome or acute coronary syndrome without ST elevation\\*.\n4. Distal vessel reference diameters ≥ 2.5 mm and ≤ 4.0 mm. \\* Non-culprit lesions eligible for revascularization in a staged procedure following a ST-elevation myocardial infarction (STEMI) are considered for inclusion.\n\nExclusion Criteria:\n\n1. Culprit lesions in acute coronary syndrome with ST elevation.\n2. Left main disease.\n3. In-stent restenosis lesions.\n4. Critical stenoses where it is not possible to advance the OCT catheter across the lesion after predilation with a balloon of up to 2 mm in diameter.\n5. Lesion involving a bifurcation with a secondary branch diameter ≥2 mm.\n6. Cardiogenic shock.\n7. Patients requiring cardiac surgery or percutaneous valve intervention within three months before or after angioplasty.\n8. Pregnancy.\n9. Life expectancy of less than one year.\n10. Contraindication for the use of appropriate antiplatelet therapy post-revascularization.\n11. Coronary artery disease with an indication for surgical revascularization.\n12. Advanced chronic kidney disease or anatomical characteristics that contraindicate the use of optical coherence tomography.\n13. Inability to obtain informed consent.\n14. Allergy to eggs or soy, contraindicating the use of OA.",{"count":272,"type":22},50,[25],"The ORBIT-SHOCK pilot study is a multicenter, prospective, randomized clinical trial initiated by investigators. It will include patients diagnosed with atherosclerotic coronary artery disease presenting calcified nodules (CN), identified by optical coherence tomography (OCT), causing significant angiographic stenosis and eligible for revascularization through percutaneous coronary intervention (PCI).\n\nPatients will be randomized in a 1:1 ratio to undergo lesion preparation with either orbital atherectomy (OA) or intravascular lithotripsy (IVL).\n\nThe ORBIT-SHOCK pilot study is a multicenter, prospective, randomized clinical trial initiated by investigators. It will include patients diagnosed with atherosclerotic coronary artery disease presenting calcified nodules (CN), identified by optical coherence tomography (OCT), causing significant angiographic stenosis and eligible for revascularization through percutaneous coronary intervention (PCI). Patients will be randomized in a 1:1 ratio to undergo lesion preparation with either orbital atherectomy (OA) or intravascular lithotripsy (IVL).\n\nThe aim of this pilot trial is to compare PCI outcomes and the incidence of adverse events between both techniques.",[276,277,278,279,280,281,114,28,282],"Coronary Arterial Disease (CAD)","Coronary Calcification","Coronary Calcified Nodules","Orbital Atherectomy","Intravascular Lithotripsy","Optical Coherence Tomography (OCT)","Acute Coronary Syndrome (ACS)",[284,285,286,287,288,281,114,28,282,269,289],"Coronary arterial disease","Coronary calcification","Coronary calcified nodules","Orbital atherectomy","Intravascular lithotripsy","ORBIT SHOCK","2026-04-26",{"date":292,"type":37},"2026-04-30",{"date":294,"type":37},"2025-06-12",{"date":296,"type":22},"2027-12",{"name":298,"class":44},"Spanish Society of Cardiology",{"id":300,"slug":301,"hasResults":12,"nctId":302,"briefTitle":303,"officialTitle":304,"acronym":305,"eligibilityCriteria":306,"healthyVolunteers":12,"sex":18,"minAge":307,"maxAge":4,"enrollmentInfo":308,"targetDuration":4,"studyType":23,"phases":310,"briefSummary":312,"conditions":313,"keywords":314,"overallStatus":91,"whyStopped":4,"lastUpdateSubmitDate":316,"lastUpdatePostDateStruct":317,"startDateStruct":319,"completionDateStruct":321,"leadSponsor":323,"locationsCount":325},"100629222","phase-4-effect-of-zastaprazan-on-platelet-reactivity-of-clopidogrel-after-percutaneous-coronary-intervention-100629222","NCT07471867","Effect of ZaStaprazan on Platelet Reactivity of Clopidogrel After PercuTaneous CoronAry InteRvention","Effect of ZaStaprazan on Platelet Reactivity of Clopidogrel After PercuTaneous CoronAry InteRvention: A Randomized Double-Blind Pilot Study (EZ-STAR)","EZ-STAR","Inclusion Criteria:\n\n1. Age 19 years or older at the time of providing informed consent.\n2. Patients with Chronic Coronary Syndrome (CCS) who have undergone Percutaneous Coronary Intervention (PCI) and agreed to participate in the study.\n3. Patients who are required to maintain dual antiplatelet therapy (DAPT) including clopidogrel for at least 6 months after PCI.\n4. Patients who have voluntarily provided written informed consent to participate in this clinical study.\n\nExclusion Criteria:\n\n1. History of hypersensitivity to P-CABs, PPIs, benzimidazoles, aspirin, clopidogrel, or any of the excipients in the study drugs.\n2. History of or planned surgery that may affect gastric acid secretion, such as upper gastrointestinal resection, acid suppression surgery, or gastric mucosal resection. (However, patients who have undergone simple perforation repair of the stomach or duodenum, appendectomy, cholecystectomy, hysterectomy, or endoscopic\u002Flaparoscopic resection of benign tumors are eligible).\n3. Diagnosis of Zollinger-Ellison syndrome or inflammatory diseases (e.g., pancreatitis, or inflammatory bowel diseases such as Crohn's disease or ulcerative colitis).\n4. Currently receiving HIV protease inhibitors (atazanavir, nelfinavir) or rilpivirine-containing products.\n5. Abnormal blood chemistry values within 4 weeks prior to screening: AST, ALT, ALP, or total bilirubin \\> 3 times the upper limit of normal (ULN). Estimated Glomerular Filtration Rate (eGFR) \\\u003C 30 mL\u002Fmin\u002F1.73m², calculated using the IDMS-traceable MDRD equation.\n6. Recent Medication Use: Use of medications expected to affect the study results, such as P2Y12 inhibitors (other than the prescribed clopidogrel), within 2 weeks prior to baseline.\n7. Pregnant or lactating women, or women with a positive pregnancy test.\n8. Patients with hereditary problems such as galactose intolerance, Lapp lactase deficiency, or glucose-galactose malabsorption.","19 Years",{"count":309,"type":22},100,[311],"PHASE4","The purpose of this study is to evaluate the clinical utility of zastaprazan compared to proton pump inhibitors (PPIs) in patients receiving dual antiplatelet therapy (DAPT) including clopidogrel after percutaneous coronary intervention (PCI), by comparing their effects on platelet reactivity.",[28],[28,315],"zastaprazan","2026-04-22",{"date":318,"type":37},"2026-04-24",{"date":320,"type":37},"2026-04-02",{"date":322,"type":22},"2028-07-12",{"name":324,"class":44},"Yonsei University",1,{"id":327,"slug":328,"hasResults":12,"nctId":329,"briefTitle":330,"officialTitle":331,"acronym":332,"eligibilityCriteria":333,"healthyVolunteers":12,"sex":18,"minAge":307,"maxAge":4,"enrollmentInfo":334,"targetDuration":4,"studyType":23,"phases":336,"briefSummary":337,"conditions":338,"keywords":340,"overallStatus":91,"whyStopped":4,"lastUpdateSubmitDate":344,"lastUpdatePostDateStruct":345,"startDateStruct":347,"completionDateStruct":349,"leadSponsor":350,"locationsCount":352},"100618290","artificial-intelligence-driven-medipixel-fractional-flow-reserve-versus-invasive-fractional-flow-reserve-guided-pci-trial-aim-ffr-trial-100618290","NCT07329699","Artificial Intelligence-Driven Medipixel Fractional Flow Reserve Versus Invasive Fractional Flow Reserve-Guided PCI Trial (AIM-FFR Trial)","Artificial Intelligence-Driven Angiography-Based Fractional Flow Reserve Versus Invasive Fractional Flow Reserve-Guided PCI","AIM-FFR","Inclusion Criteria:\n\n1. Subject must be at least 19 years of age\n2. Eligible for coronary angiography and\u002For percutaneous coronary intervention.\n3. Chronic coronary syndrome or acute coronary syndrome (non-culprit vessels only)\n4. Coronary artery disease in one or more native major epicardial vessels or their branches with reference vessel diameter of at least 2.5mm and with visually assessed coronary stenosis in which the physiological severity of the lesion is questionable (typically 40-90% diameter stenosis).\n5. Subject who is able to understand risks, benefits and treatment alternatives and sign informed consent voluntarily.\n\nExclusion Criteria:\n\n1. Patients unable to provide informed consent\n2. Patients with known intolerance to aspirin, P2Y12 inhibitors, or components of drug-eluting stents and drug-coated balloons\n3. Patients with coronary artery bypass grafting\n4. Patients who have non-cardiac co-morbid conditions with life expectancy \\\u003C1 year\n5. Patients with cardiogenic shock or cardiac arrest\n6. Patients with severe left ventricular systolic dysfunction (ejection fraction \\\u003C30%)\n7. Patients with severe valvular heart disease requiring open heart surgery\n8. Pregnant or lactating women\n9. Angiographic exclusion criteria\n\n   * Culprit vessel of patients with ST-elevation myocardial infarction (target lesions in non-culprit vessel can be enrolled)\n   * Chronic total occlusion (target lesions in vessels without chronic total occlusion can be enrolled)\n   * Ostial stenosis in left man coronary artery or right coronary artery\n   * Severe tortuosity of any target vessel\n   * Severe overlap in the stenosed segment\n   * Poor image quality precluding identification of vessel contours",{"count":335,"type":22},2100,[25],"The AIM-FFR trial is a prospective, multi-center, open-label, randomized controlled, non-inferiority trial. The current trial will evaluate non-inferiority of MPFFR-guided PCI, compared with invasive FFR-guided PCI in patients with coronary artery disease.",[61,28,339],"Acute Coronary Syndrome",[341,342,343],"Coronary artery stenosis","Fractional flow reserve","Prognosis","2026-04-21",{"date":346,"type":37},"2026-04-23",{"date":348,"type":37},"2026-03-18",{"date":98,"type":22},{"name":351,"class":44},"Samsung Medical Center",23,{"id":354,"slug":355,"hasResults":12,"nctId":356,"briefTitle":357,"officialTitle":358,"acronym":359,"eligibilityCriteria":360,"healthyVolunteers":12,"sex":18,"minAge":53,"maxAge":4,"enrollmentInfo":361,"targetDuration":4,"studyType":23,"phases":363,"briefSummary":364,"conditions":365,"keywords":368,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":373,"lastUpdatePostDateStruct":374,"startDateStruct":375,"completionDateStruct":377,"leadSponsor":379,"locationsCount":325},"100634707","right-dorsolateral-prefrontal-cortex-closed-loop-neurofeedback-for-anxiety-in-high-ischaemic-risk-chronic-coronary-syndrome-100634707","NCT07543185","Right Dorsolateral Prefrontal Cortex Closed-loop Neurofeedback for Anxiety in High-ischaemic-risk Chronic Coronary Syndrome","Right Dorsolateral Prefrontal Cortex Closed-loop Neurofeedback for Anxiety in High-ischaemic-risk Chronic Coronary Syndrome: a Randomized, Sham-controlled Trial","HEART-SET-3","Inclusion Criteria:\n\n* Participants will be aged 18 years or older and will provide written informed consent.\n* Participants will have chronic coronary syndrome (CCS) with prior coronary stent implantation more than 6 months before enrollment.\n* Participants will meet high ischemic risk (HIR) criteria by either of the following:\n\n  * Percutaneous coronary intervention (PCI) performed more than 6 months earlier for acute coronary syndrome (ACS), including unstable angina, non-ST-segment elevation myocardial infarction, or ST-segment elevation myocardial infarction, with implantation of at least 1 coronary stent; or\n  * PCI performed more than 6 months earlier for a non-ACS indication, together with at least 1 of the following risk factors:\n\n    * diabetes mellitus;\n    * diffuse multivessel coronary artery disease involving all 3 major coronary vessels;\n    * chronic kidney disease with creatinine clearance less than 50 mL\u002Fmin (recommended to be calculated using the Cockcroft-Gault formula);\n    * prior stent thrombosis;\n    * peripheral arterial disease;\n    * complex PCI, defined by at least 1 of the following:\n\n      * only patent remaining coronary vessel or left main coronary artery stenting;\n      * implantation of at least 3 stents or treatment of at least 3 lesions;\n      * bifurcation lesion treated with a 2-stent strategy;\n      * total stent length greater than 60 mm;\n      * PCI for chronic total occlusion.\n* Participants will meet DSM-5 diagnostic criteria for an anxiety disorder, confirmed by structured psychiatric interview.\n* Participants will have a Hamilton Anxiety Rating Scale (HAMA) score of 16 or higher.\n* Participants will have a 17-item Hamilton Depression Rating Scale (HAMD-17) score lower than 17.\n* Participants will not have used psychotropic medication, including antidepressants, anxiolytics, or antipsychotics, within 1 month before enrollment; prior psychotropic medication use will not itself exclude participation, provided that a washout period has been completed before enrollment and the medication history is documented.\n\nExclusion Criteria:\n\n* Participants will be excluded if they have severe congestive heart failure (New York Heart Association class IV).\n* Participants will be excluded if they have moderate-to-severe valvular heart disease.\n* Participants will be excluded if they have a history of atrial fibrillation.\n* Participants will be excluded if they have unstable blood pressure, defined as systolic blood pressure greater than 180 mmHg or less than 90 mmHg.\n* Participants will be excluded if they are pregnant or breastfeeding.\n* Participants will be excluded if they have active or recent (within 6 months) severe systemic disease, including any of the following:\n\n  * cerebrovascular disease, including stroke or transient ischemic attack;\n  * dementia or severe cognitive impairment;\n  * hyperthyroidism;\n  * active pulmonary disease;\n  * active malignant tumor.\n* Participants will be excluded if they have suicidal or homicidal risk based on clinical interview.\n* Participants will be excluded if they have other severe psychiatric disorders, including but not limited to:\n\n  * psychotic disorders, such as hallucinations or delusions;\n  * bipolar disorder.",{"count":362,"type":22},214,[25],"This study is a prospective, randomized, sham-controlled, participant- and assessor-blinded, parallel-group clinical trial designed to evaluate the clinical efficacy, mechanistic effects, and safety of right dorsolateral prefrontal cortex (DLPFC) closed-loop functional near-infrared spectroscopy brain-computer interface (fNIRS-BCI) neurofeedback in patients with high-ischaemic-risk chronic coronary syndrome (CCS) and comorbid anxiety disorder. Participants will be randomly assigned in a 1:1 ratio to active neurofeedback or sham feedback. The intervention consists of 4 weeks of treatment, with 20 sessions in total (1 session per weekday, approximately 20 minutes per session). The primary endpoint is the between-group difference in Hamilton Anxiety Rating Scale (HAMA) score at 3 months after treatment. Secondary endpoints include HAMA score and HAMA response rate at the end of treatment, as well as neurophysiological measures collected during Session 1, including right DLPFC activation, heart rate (HR), and heart rate variability (HRV). Exploratory long-term follow-up will assess cardiovascular and bleeding outcomes through 4 years after randomization.",[28,366,367],"Anxiety Disorder","High Ischemic Risk",[369,370,371,372],"closed-loop neurofeedback","fNIRS-BCI","right dorsolateral prefrontal cortex","psycho-cardiology","2026-04-14",{"date":344,"type":37},{"date":376,"type":22},"2026-04-19",{"date":378,"type":22},"2031-02-20",{"name":380,"class":44},"Shenyang Medical College",{"id":382,"slug":383,"hasResults":12,"nctId":384,"briefTitle":385,"officialTitle":386,"acronym":4,"eligibilityCriteria":387,"healthyVolunteers":12,"sex":18,"minAge":53,"maxAge":218,"enrollmentInfo":388,"targetDuration":4,"studyType":23,"phases":390,"briefSummary":391,"conditions":392,"keywords":394,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":403,"lastUpdatePostDateStruct":404,"startDateStruct":406,"completionDateStruct":408,"leadSponsor":410,"locationsCount":325},"100623093","phase-3-reversal-to-normoglycemia-by-treating-prediabetes-100623093","NCT07392151","Reversal to Normoglycemia by Treating Prediabetes","REVERsal to Normoglycemia by Treating PREDIABETES: The REVERT-PREDIABETES Trial","Inclusion Criteria:\n\n* Chronic coronary syndrome with documented coronary artery disease. In the case of previous myocardial infarction, at least 30 days between the event and randomization is required.\n* Prediabetes defined as HbA1c 42-47 mmol\u002Fmol (IEC criteria) OR normoglycemia defined as HbA1c \\\u003C39 mmol\u002Fmol\n* Age 18 to 80 years\n\nExclusion Criteria:\n\n* eGFR \\\u003C30 mL\u002Fmin\u002F1.73 m2\n* Previous diabetes diagnosis, previous HbA1c \\>47 mmol\u002Fmol, or current\u002Fprevious usage of diabetes medication\n* Anemia, recent bleeding or blood transfusion (\\\u003C3 months)\n* Previous pancreatitis\n* Pregnancy, breastfeeding, or fertile women who do not use highly effective contraception\n* Strongly reduced liver function\n* Chronic alcohol abuse\n* Known hemoglobinopathy and other conditions with effect on erythrocyte lifespan\n* Intake of medications with known effect on HbA1c validity such as: antiretroviral medications, trimethoprim, sulfamethoxazole, sulfasalazine hydroxyurea, dapsone, acetylsalicylic acid (\\>3 g\u002Fdaily), high dose vitamin C and E.\n* Heart failure with NYHA class III or IV Trial subjects must be capable of giving informed consent as assessed by the investigator.\n\nPatients with BMI\\\u003C25 kg\u002Fm2 will be assessed individually by an investigator for eligibility (e.g., whether initiation of a GLP-1 RA with potential weight loss is clinically justifiable).",{"count":389,"type":22},158,[138],"Prediabetes is a precursor to diabetes, but compared with diabetes, much less is known about prediabetes. Prediabetes is defined based on a blood sample measuring long-term average glucose levels. In the Danish population, about 7% have prediabetes, and roughly one in five will develop diabetes within five years. In the US, significantly more people have this condition - about 38% of the adult population - and it is reasonable to expect a growing global prevalence over the years.\n\nDiabetes is associated with various microvascular diseases, traditionally referred to as diabetic complications, such as diabetic retinopathy, diabetic nephropathy, and diabetic neuropathy. However, it has been shown that some of these conditions are already present in some individuals with prediabetes, even though this condition does not meet the diagnostic criteria for diabetes. Several metabolic changes are often seen in people with prediabetes, including high cholesterol, hypertension, increased inflammatory markers, and obesity. Additionally, there is a possible link between prediabetes and the occurrence of fat accumulation in the liver. These risk factors are also believed to be associated with the development of coronary atherosclerosis. In individuals with coronary atherosclerosis there is an overrepresentation of prediabetes. Therefore, the investigators would like to investigate whether this group of people might benefit from having their long-term average glucose levels reduced to normal from prediabetes using glucose-lowering medication, which is approved for use in people with diabetes and has also shown a cardioprotective effect in individuals without diabetes.\n\nThe medications that will be used for this purpose are:\n\nSemaglutide, administered once weekly as a subcutaneous injection. The dose will be gradually increased at 4-week intervals up to a maximum of 2.4 mg. If this is insufficient, it may be considered to start Dapagliflozin (Forxiga), 10 mg tablet daily. Both treatments are approved for use in Europe but are not currently used to treat prediabetes.\n\nA total of 108 individuals with prediabetes and coronary atherosclerosis who consent to participate in the trial will be randomly assigned (1:1) to two groups:\n\n1. Interventional therapy arm: Participants will attend visits at Aarhus University Hospital and begin glucose-lowering treatment. Additionally, any hypertension or high cholesterol will be optimized according to current guidelines. They will be offered lifestyle counselling. Participants will have their blood pressure measured regularly and, if necessary, blood samples are drawn to optimize the above.\n2. Conventional therapy arm: Participants will receive standard treatment either at the hospital or from their general practitioner, without any influence from the trial and without starting trial-related medication.\n\nFurthermore, a third group of 50 participants with coronary atherosclerosis and normal long-term average glucose levels will be included.\n\nAll trial participants will, at inclusion, be examined for the presence of diabetic nephropathy, diabetic neuropathy, diabetic retinopathy, and liver fat accumulation. This will be done through blood samples, urine samples, nerve examinations, and liver ultrasound. In addition, height, weight, waist circumference, body muscle and fat composition, pulse, and blood pressure will be measured. The third group will then conclude their participation.\n\nThe interventional therapy arm will begin the described intervention, which lasts for one year. After one year, the intervention period will end. Both randomized groups will then be examined by blood samples, urine samples, liver ultrasound, height, weight, waist circumference, body muscle and fat composition, pulse, and blood pressure. One year later, the above examinations will be repeated, except for the liver ultrasound. This will mark the end of the trial.",[393,28],"Prediabetes",[393,148,395,396,397,398,399,400,401,402],"Coronary artery disease","Normoglycemia","Semaglutide","Dapagliflozin","Retinopathy","Neuropathy","Nephropathy","MASLD","2026-02-02",{"date":405,"type":37},"2026-02-06",{"date":407,"type":22},"2026-02",{"date":409,"type":22},"2029-10",{"name":411,"class":44},"Michael Mæng",{"id":413,"slug":414,"hasResults":12,"nctId":415,"briefTitle":416,"officialTitle":416,"acronym":417,"eligibilityCriteria":418,"healthyVolunteers":12,"sex":18,"minAge":53,"maxAge":4,"enrollmentInfo":419,"targetDuration":4,"studyType":57,"phases":4,"briefSummary":421,"conditions":422,"keywords":423,"overallStatus":91,"whyStopped":4,"lastUpdateSubmitDate":426,"lastUpdatePostDateStruct":427,"startDateStruct":429,"completionDateStruct":431,"leadSponsor":432,"locationsCount":325},"100542022","computational-modelling-of-myocardial-perfusion-to-improve-outcome-prediction-based-on-coronary-artery-stenosis-and-atherosclerotic-plaque-burden-assessment-by-computed-tomography-100542022","NCT06337461","Computational mOdelliNg of myoCardial pERfusion to Improve ouTcome Prediction Based on cOronary Artery Stenosis and Atherosclerotic Plaque Burden Assessment by Computed Tomography","CONCERTO","Inclusion Criteria:\n\n* Symptomatic patients with suspected CAD referred for nonemergent, clinically indicated non-invasive coronary angiography.\n\nExclusion Criteria:\n\n* Low pre-test likelihood of CAD\n* Prior myocardial infarction\n* Previous history of revascularization\n* Acute coronary syndrome\n* Need for an emergent procedure\n* Evidence of clinical instability\n* Contraindication for contrast agent or impaired renal function\n* Inability to sustain a breath-hold\n* Pregnancy\n* Atrial fibrillation or flutter\n* BMI \\> 35kg\u002Fm2\n* Presence of pm or ICD\n* Contraindications to the administration of sublingual nitrates, betablockade, and adenosine",{"count":420,"type":22},400,"Detection of coronary stenosis is of utmost importance in identifying vulnerable patients. The combined use of coronary computed tomography angiography at rest (CCTA) and stress myocardial computed tomography perfusion (stress-CTP) provides both anatomic and functional analysis of coronary artery disease (CAD) using a single imaging test. Stress-CTP evaluates myocardial perfusion by measuring myocardial blood flow (MBF) under pharmacologically induced stress conditions. The drawback is that stress-CTP requires additional scanning and administration of an intravenous stressor with an increase in radiation exposure and potential stressor-related side effects. The investigators recently patented a computational model that can reproduce MBF under stress conditions (Italian patent n. 102021000031475 Metodo implementato mediante computer per la simulazione del flusso sanguigno miocardico in condizioni di stress \\[Computational method for simulating myocardial blood flow in stress conditions\\], half owned by Centro Cardiologico Monzino, half by Politecnico di Milano).\n\nOn top of this, CCTA can characterize plaque type and identify adverse plaque characteristics. Moreover, biomechanics analysis allows the study of luminal stenosis and stress within the plaque. Finally, radiomics, extracting quantitative features from medical images to create big data and identify novel imaging biomarkers, can be applied to improve the diagnostic accuracy of coronary plaques.",[28],[424,425],"CT Perfusion","Myocardial Blood Flow","2026-01-30",{"date":428,"type":37},"2026-02-03",{"date":430,"type":37},"2023-05-22",{"date":69,"type":22},{"name":433,"class":44},"Centro Cardiologico Monzino",{"id":435,"slug":436,"hasResults":12,"nctId":437,"briefTitle":438,"officialTitle":439,"acronym":440,"eligibilityCriteria":441,"healthyVolunteers":12,"sex":18,"minAge":53,"maxAge":442,"enrollmentInfo":443,"targetDuration":4,"studyType":23,"phases":445,"briefSummary":446,"conditions":447,"keywords":4,"overallStatus":91,"whyStopped":4,"lastUpdateSubmitDate":448,"lastUpdatePostDateStruct":449,"startDateStruct":451,"completionDateStruct":453,"leadSponsor":455,"locationsCount":457},"100585003","effect-of-intensive-lipid-lowering-therapy-on-coronary-atherosclerotic-plaque-progression-in-young-and-middle-aged-patients-with-chronic-coronary-syndrome-100585003","NCT06896708","Effect of Intensive Lipid-Lowering Therapy on Coronary Atherosclerotic Plaque Progression in Young and Middle-Aged Patients With Chronic Coronary Syndrome","Coronary Computed Tomography Study to Assess the Effect of Intensive Lipid-Lowering Therapy on Coronary Atherosclerotic Plaque Progression in Young and Middle-Aged Patients With Chronic Coronary Syndrome: A Nationwide, Multicentre, Randomized Controlled Trial","CAPITAL-PLAQUE","Inclusion Criteria:\n\n1\\. Aged 18-60 years at screening 2. Stable angina symptoms with suspected or confirmed coronary artery disease; 2. CCTA examination demonstrating: at least one major coronary artery with a diameter of ≥1.5mm that has not been intervened and at least one leision with 50%-70% stenosis.\n\n3\\. Subjects who have been using statin therapy alone for at least 4 weeks prior to enrollment with a baseline LDL-C ≥1.8mmol\u002FL or subjects who have not initiated lipid-lowering therapy prior to enrollment with a baseline LDL-C≥2.6mmol\u002FL.\n\nExclusion Criteria:\n\n1. Left main coronary artery disease or severe three-vessel disease;\n2. Ultra-high-risk ASCVD patients: ≥2 severe ASCVD events or 1 severe ASCVD event with ≥2 high-risk factors;\n3. Use of PCSK9 inhibitors or ezetimibe within 8 weeks prior to study enrollment;\n4. The baseline LDL-C was relatively high (LDL-C≥2.6 mmol\u002FL in those taking statins and ≥4.9 mmol\u002FL in those not taking statins).\n5. Familial hypercholesterolemia;\n6. Known allergy\u002Fintolerance to lipid-lowering drugs used in the trial;\n7. Patients with severe congestive heart failure, liver or kidney dysfunction, or malignancy;\n8. Pregnant or breastfeeding female patients.","60 Years",{"count":444,"type":22},766,[25],"This is a multicenter, open-label, parallel-group, randomized trial to determine if intensive lipid-lowering therapy (goal for LDL-C \\\u003C1.0 mmol\u002FL and ≥50% reduction frome baseline) could delay progression of coronary atherosclerotic obstructive leisions compared with guideline recommended lipid-lowering therapy (goal for LDL-C \\\u003C1.8 mmol\u002FL and ≥50% reduction frome baseline) among participants between 18-60 years old with non-invasively managed chronic coronary syndrome (at least one lesion with a 50%-70% stenosis).",[28],"2025-12-09",{"date":450,"type":37},"2025-12-17",{"date":452,"type":37},"2025-08-12",{"date":454,"type":22},"2028-03-01",{"name":456,"class":44},"Liu yong",7,{"id":459,"slug":460,"hasResults":12,"nctId":461,"briefTitle":462,"officialTitle":463,"acronym":464,"eligibilityCriteria":465,"healthyVolunteers":12,"sex":18,"minAge":53,"maxAge":4,"enrollmentInfo":466,"targetDuration":4,"studyType":23,"phases":468,"briefSummary":469,"conditions":470,"keywords":472,"overallStatus":91,"whyStopped":4,"lastUpdateSubmitDate":477,"lastUpdatePostDateStruct":478,"startDateStruct":480,"completionDateStruct":482,"leadSponsor":484,"locationsCount":325},"100505762","perfusion-estimation-for-optimal-treatment-strategy-in-chronic-coronary-syndrome-100505762","NCT05865600","Perfusion Estimation For Optimal Treatment Strategy in Chronic Coronary Syndrome","Perfusion Estimation for Optimal Revascularization and Medical Therapy in Chronic Coronary Syndrome - a Randomized Trial","PERFORM-CCS","Inclusion Criteria:\n\n1. Age \\> 18 years\n2. Willing to participate and able to understand, read and sign the informed consent document before the planned procedure\n3. Known ischemic heart disease defined as one of the following\n\n   1. Previous myocardial infarction, percutaneous coronary intervention or coronary artery bypass grafting\n   2. Previous coronary computed tomography angiography or invasive coronary angiography documenting atherosclerosis.\n4. Undergoing clinically indicated \\[15O\\]H2O cardiac PET\u002FCT due to chest discomfort or dyspnea as angina equivalent\n\n   Additional inclusion criteria for randomized trial:\n5. Initial \\[15O\\]H2O cardiac PET\u002FCT with abnormal perfusion defined as all of the following\n\n   1. Hyperemic myocardial blood flow (hMBF) ≤2.3 mL\u002Fmin\u002Fg in at least two adjacent myocardial segments\n   2. Relative hMBF ≤ 65% in at least two adjacent segments as compared with the mean hMBF of the two adjacent segments with the highest mean hMBF\n   3. Tissue perfusion defect extent ≥ 5% based on indices of relative hypoperfusion\n6. Clinical indication for invasive coronary angiography decided at a multidisciplinary conference between consultants in nuclear medicine and cardiology\n\nExclusion Criteria:\n\n1. Ongoing acute coronary syndrome or acute coronary syndrome within 30 days\n2. Contraindications for adenosine\n\n   1. Severe asthma\n   2. Advanced atrioventricular block without pacemaker\n   3. Severe aortic stenosis\n3. Patients not able to breath hold (severe COPD\u002Fasthma)\n4. Pregnant women, including women who are potentially pregnant or lactating\n5. Allergy to iomeron\n6. Life expectancy of less than 2 years\n7. Severe valvular disease\n8. Reduced kidney function with an estimated glomerular filtrations rate \\\u003C40 ml\u002Fmin\n9. Inability to consent\n\n   Additional exclusion criteria for randomized trial:\n10. Unprotected left main coronary artery stenosis on coronary CT angiography\n11. Very large perfusion defect on initial \\[15O\\]H2O cardiac PET\u002FCT indicating left main coronary artery stenosis or balanced ischemia defined as tissue perfusion defect extent based on indices of absolute hMBF ≥ 20% in two or more myocardial territories supplied by coronary arteries with an Agatston calcium score ≥ 300",{"count":467,"type":22},570,[25],"We will establish a cohort of 570 symptomatic chronic coronary syndrome patients undergoing 15O-water PET and assess their symptoms through repeated questionnaires. Two hundred patients with abnormal perfusion will be randomized to immediate or delayed referral to invasive coronary angiography with concomitant optimization of guideline-directed medical therapy with repeated 15O-water PET and questionnaires at 3 and 6 months. The primary objective is to compare the potential benefit of early invasive coronary angiography (ICA) versus guideline directed medical therapy (GDMT) on symptomatic relief defined as freedom of angina after 3 months following a positive \\[15O\\]H2O cardiac PET\u002FCT in patients with symptomatic chronic coronary syndrome.",[28,225,471,61],"Stable Angina",[225,473,61,474,475,476],"Angina Pectoris","Coronary Angiography","Computed Tomography Angiography","Myocardial Perfusion Imaging","2025-12-03",{"date":479,"type":37},"2025-12-10",{"date":481,"type":37},"2023-05-23",{"date":483,"type":22},"2027-09-01",{"name":485,"class":44},"Gødstrup Hospital",{"id":487,"slug":488,"hasResults":12,"nctId":489,"briefTitle":490,"officialTitle":491,"acronym":492,"eligibilityCriteria":493,"healthyVolunteers":12,"sex":18,"minAge":307,"maxAge":4,"enrollmentInfo":494,"targetDuration":4,"studyType":23,"phases":496,"briefSummary":497,"conditions":498,"keywords":499,"overallStatus":91,"whyStopped":4,"lastUpdateSubmitDate":502,"lastUpdatePostDateStruct":503,"startDateStruct":505,"completionDateStruct":507,"leadSponsor":509,"locationsCount":158},"100573180","drug-coated-balloon-versus-drug-eluting-stent-for-treatment-of-de-novo-coronary-lesions-in-patients-with-high-bleeding-risk-2-100573180","NCT06742931","Drug-Coated Balloon Versus Drug-Eluting Stent for Treatment of De-Novo Coronary Lesions in Patients With High Bleeding Risk-2","Discontinuation of Antiplatelet Agent After Drug-Coated Balloon Angioplasty in Stabilized Patients With High Bleeding Risk and Coronary Artery Disease","DCB-HBR-2","Inclusion Criteria:\n\n1. Subject must be at least 19 years of age\n2. Subject who is able to understand risks, benefits and treatment alternatives and sign informed consent voluntarily.\n3. Patients with chronic coronary syndrome and at least one de novo lesion of reference vessel size ≥2.25 mm, treated with DCB angioplasty\n4. Patients with high bleeding risk: one or more of the criteria listed A. Age ≥ 75 years old B. Baseline Hemoglobin \\\u003C11 g\u002Fdl (or anemia requiring transfusion during the 4 weeks prior to randomization) C. Any prior intra-cerebral bleed D. Hospital admission for bleeding during the prior 12 months E. Non skin cancer diagnosed or treated \\\u003C 3 years F. Planned daily NSAID (other than aspirin) or steroids for \\>30 days after PCI G. Planned surgery that would require interruption of DAPT (within next 12 months) H. Renal failure defined as calculated creatinine clearance \\\u003C40 ml\u002Fmin or on dialysis I. Hematological disorders (platelet count \\\u003C100,000\u002Fmm3 or any coagulation disorder) J. Severe chronic liver disease defined as patients who have developed any of the following: variceal hemorrhage, ascites, hepatic encephalopathy or jaundice K. Expected non-compliance to secondary prevention medications after PCI for other medical reasons\n5. Patients who completed standard duration of DAPT (1-3months) and followed by maintenance of single antiplatelet agent (aspirin or P2Y12 inhibitor) for at least 1 year from index procedure.\n6. No bleeding (BARC 2, 3, or 5 bleeding) or ischemic events (cardiovascular death, non-fatal MI, or clinically-indicated repeat revascularization) for at least 1 year from index procedure.\n\nExclusion Criteria:\n\n1. Patients unable to provide consent\n2. Patients with acute myocardial infarction or unstable angina\n3. Patients with known intolerance to aspirin, P2Y12 inhibitors, or components of DCB\n4. Patients with indication of oral anticoagulant\n5. Patients with concomitant drug-eluting stent implantation during index PCI\n6. Patients with history of ischemic stroke or previous myocardial infarction\n7. Patients with peripheral arterial occlusive disease\n8. Patients with angiographic findings of A. Left main coronary artery disease B. In-stent restenosis is the cause of target lesion C. Target lesion in bypass graft D. True bifurcation lesion that requires upfront 2-stenting E. Patients with residual stenosis on non-target vessels after PCI (\\>70% diameter stenosis or FFR≤0.80)\n9. Patients who have non-cardiac co-morbid conditions with life expectancy \\\u003C1 year\n10. Patients who may result in protocol non-compliance (site investigator's medical judgment)\n11. Patients with cardiogenic shock or cardiac arrest\n12. Patients with severe left ventricular systolic dysfunction (ejection fraction \\\u003C30%)\n13. Patients with severe valvular heart disease requiring open heart surgery\n14. Pregnant or lactating women",{"count":495,"type":22},1200,[25],"A prospective, multi-center, open-label, randomized controlled, and superiority trial. The trial will compare clinical outcomes between discontinuation of antiplatelet agent and continuation of antiplatelet agent in HBR patients with chronic coronary syndrome treated by DCB angioplasty and standard duration of DAPT, followed by maintenance of single antiplatelet agent without clinical event for at least 1 year from the index procedure.",[28],[341,500,501,148,343],"Antiplatelet agent","Drug-coated balloon","2025-11-21",{"date":504,"type":37},"2025-11-28",{"date":506,"type":37},"2025-04-07",{"date":508,"type":22},"2031-12-31",{"name":351,"class":44},{"id":511,"slug":512,"hasResults":12,"nctId":513,"briefTitle":514,"officialTitle":515,"acronym":516,"eligibilityCriteria":517,"healthyVolunteers":12,"sex":18,"minAge":53,"maxAge":4,"enrollmentInfo":518,"targetDuration":4,"studyType":23,"phases":520,"briefSummary":521,"conditions":522,"keywords":524,"overallStatus":91,"whyStopped":4,"lastUpdateSubmitDate":528,"lastUpdatePostDateStruct":529,"startDateStruct":530,"completionDateStruct":532,"leadSponsor":533,"locationsCount":325},"100530342","secure-trial-stress-echocardiography-with-carotid-ultrasound-vs-routine-ct-coronary-angiography-in-chronic-coronary-syndrome-for-endpoints-100530342","NCT06185530","SECURE Trial: Stress Echocardiography With Carotid Ultrasound vs Routine CT Coronary Angiography in Chronic Coronary Syndrome for Endpoints","Stress Echocardiography With Carotid Ultrasound vs Routine CT Coronary Angiography in Suspected Chronic Coronary Syndrome for the Detection of Obstructive Coronary Disease and Prevention of Adverse Outcomes.","SECURE","Inclusion Criteria:\n\n1. Age \\> 18 years old\n2. Patients referred to RACPC and judged by the reviewer to require a further imaging investigation, either SE or CTCA, to evaluate a suspected diagnosis of CAD\n3. AND\n\n   1. Have a PTP score ≥ 5%, as calculated using ESC guidelines OR\n   2. Have clinical history in keeping with 'typical' angina symptoms, as judged by the investigator, in patients with a PTP score \\\u003C5% - With 'typical' symptoms, as per ESC guidelines, being all three of the following\n\n   i) Constricting symptoms in the front of the chest or in the neck, jaw, shoulder or arm ii) Precipitated by physical exertion iii) Relieved by rest or nitrates within 5 minutes\n4. Able to give informed consent to participate in the study and its follow up\n\nExclusion Criteria:\n\n1. Patients with diagnosed ACS that require urgent or emergency treatment or hospitalisation for inpatient investigations.\n2. Known history of obstructive CAD (Previous MI, PCI or CABG) or previous invasive angiography with evidence of ≥ 50% stenosis in any epicardial vessel.\n3. Patients who have undergone invasive or non-invasive, functional or anatomical (Including CAC score) testing for detection of CAD within the previous 1 year of clinical assessment.\n4. Documented allergy to iodinated contrast or documented allergy to both ultrasound contrasts used at LNWH Trust; Luminity® (Perflutren) and SonoVue® (Sulphur Hexafluoride) or the constitutes\n5. Contraindications to undergoing CTCA, including but not limited to;\n\n   * eGFR \\\u003C 40 ml\u002Fmin\n   * Contraindications to beta-blockers including but not limited to, documented allergy or significant airways disease in the judgement of the investigator.\n   * Exceeding CT scanner weight tolerance\n6. Contraindications to undergoing SE, including but not limited to;\n\n   * Known cardiomyopathic process (Hypertrophic cardiomyopathy (HCM)) with resting gradient \\> 50mmHg or severe valvular lesion\n   * Severe uncontrolled hypertension (≥180\u002F100mmHg)\n7. Known pregnancy\n8. Unable to provide informed consent",{"count":519,"type":22},2000,[25],"Diseases of the heart and circulation are known as cardiovascular diseases, and they cause over 160,000 deaths each year.\n\nCoronary heart disease (CHD) is the most common cardiovascular disease. This is due to a build-up of fatty material, known as atherosclerosis, in the blood vessels supplying blood to the heart muscle. This can cause chest pain or if blocked, can cause a heart attack.\n\nTwo of the main non-invasive tests to look for coronary heart disease are Computed Tomography Coronary Angiography (CTCA) and Stress Echocardiography (Ultrasound scan).\n\nCTCA shows the arteries and allows small amounts of disease to be seen that may not yet be causing any symptoms. However, if there's lots of disease and calcification, it becomes difficult to tell how severe it is, which means several tests may be needed. Stress Echocardiography shows if enough blood is reaching the heart muscle, so can show if there is severe disease that needs treatment. However, it can't see the arteries so doesn't showt small disease that may benefit from tablet treatment. There is not yet an effective non-invasive combined test that can give all this information in one go.\n\nStudies have shown that if there's atherosclerosis in another artery, a person is very likely to have coronary atherosclerosis as well. Carotid atherosclerosis, in the neck arteries, can be seen with ultrasound similar to stress echocardiography. So, by combining these two tests the investigators want to see if it is possible to see severe as well as small areas of disease in one test, to provide better treatment.\n\nThe study will enrol 2,000 participants, who need investigation for CHD, equally randomised to CTCA or stress echocardiography with carotid ultrasound. We will follow these participants for 5 years and observe for any adverse outcomes and ask them to complete a questionnaire.",[28,523,61],"Coronary Disease",[525,526,527],"CTCA","Stress Echocardiography","Carotid Ultrasound","2025-11-20",{"date":502,"type":37},{"date":531,"type":37},"2023-09-18",{"date":508,"type":22},{"name":534,"class":44},"London North West Healthcare NHS Trust",{"id":536,"slug":537,"hasResults":12,"nctId":538,"briefTitle":539,"officialTitle":540,"acronym":4,"eligibilityCriteria":541,"healthyVolunteers":12,"sex":18,"minAge":53,"maxAge":4,"enrollmentInfo":542,"targetDuration":4,"studyType":57,"phases":4,"briefSummary":544,"conditions":545,"keywords":4,"overallStatus":91,"whyStopped":4,"lastUpdateSubmitDate":546,"lastUpdatePostDateStruct":547,"startDateStruct":549,"completionDateStruct":551,"leadSponsor":553,"locationsCount":325},"100589494","a-study-on-the-peripheral-blood-in-patients-with-acute-coronary-syndrome-100589494","NCT06955143","A Study on the Peripheral Blood in Patients With Acute Coronary Syndrome","A Study on Integrated Multi-Omics and Multi-Factor Analysis of Peripheral Blood in Patients With Acute Coronary Syndrome","Inclusion Criteria:\n\nFor ACS group STEMI\n\n* cTn\\>99th ULN or CK-MB\\>99th ULN\n* ST-segment elevation with a convex upward morphology\n* in conjunction with one or more of the following conditions: persistent ischemic chest pain; echocardiographic evidence of abnormal segmental ventricular wall motion; or abnormal coronary angiography findings.\n\nNSTEMI\n\n* cTn\\>99th ULN or CK-MB\\>99th ULN\n* accompanied by one or more of the following situations: persistent ischemic chest pain; new ST-segment depression or low and inverted T waves; echocardiography showing segmental ventricular wall motion abnormalities; abnormal coronary angiography.\n\nUA\n\n* cTn normal\n* ischemic chest pain with an electrocardiogram showing transient ST-segment depression or flattened and inverted T waves\n* evidence of coronary artery stenosis (e.g., CTA demonstrating ≥ 50% stenosis) For CCS group\n* Clinical Diagnosis Consistent with CCS Categories, meet any one of the following clinical scenarios: Stable Angina Pectoris, Ischemic Cardiomyopathy, Post-ACS Stable Phase, Long-Term CAD Management, Vasospastic or Microvascular Disease, Asymptomatic CAD\n* Laboratory and Imaging Confirmation: Resting ECG without ST-segment elevation or dynamic changes (excluding ACS), cTn normal or stable (no acute myocardial injury), ≥50% luminal stenosis in ≥1 epicardial coronary artery For control group\n* Patients without coronary artery stenosis, valvular heart disease, structural heart disease, or any other kind of cardiomyopathy\n\nExclusion Criteria:\n\n* Lactating or pregnant women\n* Patients with malignant neoplasms\n* Severe hepatic\u002Frenal dysfunction\n* Severe hematological disorders\n* Autoimmune diseases",{"count":543,"type":22},310,"The goal of this study is to conduct analyses the changes of cell growth factors, inflammatory factors, metabolites, plasma proteome, etc. in the blood of patients with ACS (acute coronary syndrome), as well as their correlations with the disease prognosis, based on multi-omics or other related research methods. The main questions it aims to answer are:\n\nThe growth factors that have significant changes in the peripheral blood of the ACS population, especially fibroblast growth factors? Inflammatory factors and chemokines related to the onset of ACS? The metabolites and proteins that are significantly altered in the peripheral blood after the onset of ACS? Researchers will compare ACS population to CCS (Chronic Coronary Syndrome) population, and control group (patients without coronary artery stenosis, valvular heart disease, structural heart disease, or any other kind of cardiomyopathy).The peripheral venous blood from the participants will be collected within 24 hours after their admission to the hospital.",[339,28],"2025-07-21",{"date":548,"type":37},"2025-07-25",{"date":550,"type":37},"2025-03-11",{"date":552,"type":22},"2025-12",{"name":554,"class":44},"Second Affiliated Hospital of Wenzhou Medical University",{"id":556,"slug":557,"hasResults":12,"nctId":558,"briefTitle":559,"officialTitle":560,"acronym":561,"eligibilityCriteria":562,"healthyVolunteers":12,"sex":18,"minAge":53,"maxAge":4,"enrollmentInfo":563,"targetDuration":4,"studyType":23,"phases":565,"briefSummary":566,"conditions":567,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":568,"lastUpdatePostDateStruct":569,"startDateStruct":571,"completionDateStruct":573,"leadSponsor":575,"locationsCount":4},"100599145","phase-4-short-term-dual-antiplatelet-therapy-with-early-transi-tion-to-low-dose-antiplatelet-monotherapy-using-ti-cagrelor-in-chronic-coronary-artery-disease-100599145","NCT07080684","Short-Term Dual Antiplatelet Therapy With Early Transi-tion to Low-dose Antiplatelet Monotherapy Using Ti-cagRelor in Chronic Coronary Artery Disease","Short-Term Dual Antiplatelet Therapy With Early Transition to Low-dose Antiplatelet Monotherapy Using ticagRelor in Chronic Coronary Artery Disease","STELAR","Inclusion Criteria:\n\n* Age ≥18 years at the time of informed consent.\n* Diagnosis of chronic coronary syndrome (CCS) according to ESC guidelines.\n* Undergoing successful PCI with implantation of one or more new-generation drug-eluting stents (DES).\n* Indication for dual antiplatelet therapy (DAPT) following PCI.\n* Willingness and ability to comply with all study procedures and follow-up assessments.\n* Signed informed consent prior to any study-specific procedure.\n* Creatinine clearance ≥30 mL\u002Fmin, calculated using the Cockcroft-Gault formula.\n* Life expectancy greater than 1 year in the investigator's judg-ment.\n* Hemodynamically stable at the time of randomization.\n* Acceptable bleeding risk profile: patients fulfilling ARC-HBR criteria may be included only if the treating physician deems a 6-month antiplatelet regimen to be safe.\n* No contraindications to study drugs, including aspirin, clopi-dogrel, or ticagrelor.\n\nExclusion Criteria:\n\n* Presentation with acute coronary syndrome (ACS), including STEMI, NSTEMI, or unstable angina within the previous 6 mon-ths.\n* Planned staged PCI or revascularization procedure within 6 months after index PCI.\n* Requirement for long-term oral anticoagulation therapy, such as for atrial fibrillation, mechanical heart valves, or venous thromboembolism.\n* History of major bleeding, including gastrointestinal or intra-cranial bleeding, within the past 6 months.\n* Severe hepatic impairment, active liver disease, or transamina-ses \\>3× upper limit of normal.\n* Known platelet disorder, coagulopathy, or thrombocytopenia (\\\u003C100,000\u002Fmm³).\n* Contraindication or hypersensitivity to aspirin, clopidogrel, or ticagrelor, or known drug interaction that precludes their use.\n* Ongoing active bleeding or high risk of bleeding that, in the opinion of the investigator, precludes DAPT.\n* Pregnancy or breastfeeding, or women of childbearing potential who are not using effective contraception.\n* Life expectancy \\\u003C1 year due to non-cardiovascular comorbidi-ties (e.g., cancer, advanced renal failure).\n* Participation in another interventional clinical trial that may interfere with the outcomes of this study.\n* Severe anemia (hemoglobin \\\u003C9 g\u002FdL) not corrected before ran-domization.\n* Inability or unwillingness to provide informed consent or ad-here to study follow-up.\n* Prior stroke with residual neurological deficit or history of di-sabling stroke (mRS ≥3).",{"count":564,"type":22},1000,[311],"This is a prospective, multicenter, randomized, open-label trial with blinded endpoint adjudication (PROBE design), comparing one-month dual antiplatelet therapy (DAPT) with low-dose ticagrelor (60 mg BID) followed by ticagrelor monotherapy to standard 6-month DAPT with aspirin and clopidogrel in patients with chronic coronary syndrome (CCS) undergoing percutaneous coronary intervention (PCI). The primary endpoint is a composite of cardiovascular death, all-cause death, myocardial infarction, disabling stroke, target lesion revascularization (TLR), and major bleeding. The study aims to evaluate whether the short DAPT strategy reduces ischemic events while maintaining bleeding safety.",[28],"2025-07-14",{"date":570,"type":37},"2025-07-23",{"date":572,"type":22},"2025-12-01",{"date":574,"type":22},"2027-09",{"name":576,"class":44},"University of Messina",{"id":578,"slug":579,"hasResults":12,"nctId":580,"briefTitle":581,"officialTitle":581,"acronym":582,"eligibilityCriteria":583,"healthyVolunteers":584,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":585,"targetDuration":4,"studyType":23,"phases":587,"briefSummary":588,"conditions":589,"keywords":591,"overallStatus":91,"whyStopped":4,"lastUpdateSubmitDate":595,"lastUpdatePostDateStruct":596,"startDateStruct":598,"completionDateStruct":600,"leadSponsor":602,"locationsCount":325},"100560521","phase-4-hyperemic-myocardial-perfusion-by-adenosine-at-different-doses-100560521","NCT06578234","Hyperemic mYocardial Perfusion by adEnosine at diffeRent Doses","HYPER","Inclusion Criteria:\n\nPatients:\n\n1. The subject has given their written consent to participate in the trial.\n2. Are referred to Department of Clinical Physiology, Skåne University Hospital, for suspected or known CCS or heart failure\n3. Matches the inclusion criteria for sex and age (6 females and 6 males from each group in each age decade from 40 to \\>80 years old)\n4. Matches the inclusion criteria for no known heart failure (group b) or known heart failure (group c)\n5. No caffein intake \\\u003C24h prior to the examination\n\nHealthy volunteers:\n\n1. The subject has given their written consent to participate in the trial.\n2. Matches the inclusion criteria for sex and age (6 females and 6 males from each group in each age decade from 40 to \\>80 years old)\n3. No caffein intake \\\u003C24h prior to the examination\n\nExclusion Criteria:\n\nPatients:\n\n1. Acute referral (in-house patients)\n2. Clinically unstable\n3. Acute chest pain\n4. Severe or decompensated heart failure\n5. Non sinus rhythm (e.g. atrial fibrillation)\n6. Asthma or severe chronic obstructive pulmonary disease\n7. Known chronic renal failure (eGFR \\\u003C45mL\u002Fmin\u002F1.73m2)\n8. AV-block II or III\n9. Left Bundle Branch Block\n10. Systolic blood pressure \\\u003C90 mmHg or \\>230 mmHg at rest\n11. Increased intracranial pressure\n12. Known allergy or adverse reaction to adenosine or mannitol\n13. Known allergy or adverse reaction to gadolinium contrast agents\n14. Treatment with medication containing dipyradimol or teofyllamin\u002Fteofyllin\n15. Claustrophobia\n16. Devices contraindicated to CMR imaging (pacemaker, implants, intracranial clips etc)\n17. Pregnancy or breast feeding (screened by question only)\n18. Inability to give informed consent due to mental state, language difficulties etc\n\nHealthy volunteers:\n\n1. Any of the exclusion criteria for patients\n2. Blood pressure \\> 140\u002F90 measured according to clinical routine\n3. Known systemic disease\n4. Known cardiac disease\n5. Cardiovascular medication\n6. Medication that might influence cardiovascular health\n7. Smoking",true,{"count":586,"type":22},180,[311],"Adenosine is a commonly used pharmaceutical stressor at cardiac magnetic resonance examinations to assess suspected chronic coronary syndrome (CCS). However, several studies have reported that the current use of adenosine does not induce adequate hyperemic response in a substantial number of patients, leading to false diagnostics. The aim of this trial is to investigate the hyperemic effect of the standard dose of adenosine (140 microgram\u002Fkg\u002Fmin) to the high dose of adenosine (210 microgram\u002Fkg\u002Fmin) to improve the diagnostic methods using adenosine as a stressor and ultimately improve treatment decisions and patient prognosis in CCS.",[28,61,590],"Ischemic Heart Disease",[592,593,594],"Myocardial perfusion","Cardiac Magnetic Resonance","Adenosine","2025-06-26",{"date":597,"type":37},"2025-06-27",{"date":599,"type":37},"2024-10-23",{"date":601,"type":22},"2026-12-31",{"name":603,"class":44},"Region Skane",{"id":605,"slug":606,"hasResults":12,"nctId":607,"briefTitle":608,"officialTitle":609,"acronym":610,"eligibilityCriteria":611,"healthyVolunteers":12,"sex":18,"minAge":53,"maxAge":4,"enrollmentInfo":612,"targetDuration":614,"studyType":57,"phases":4,"briefSummary":615,"conditions":616,"keywords":618,"overallStatus":91,"whyStopped":4,"lastUpdateSubmitDate":625,"lastUpdatePostDateStruct":626,"startDateStruct":628,"completionDateStruct":630,"leadSponsor":632,"locationsCount":325},"100594546","fapi-imaging-predicts-adverse-cardiac-events-in-chronic-total-occlusion-100594546","NCT07020858","FAPI Imaging Predicts Adverse Cardiac Events in Chronic Total Occlusion","The Value of FAPI Imaging for the Prediction of Adverse Cardiovascular Events in Chronic Total Occlusion of Coronary Artery Disease (FACT-2 Trial)","FACT-2","Inclusion Criteria:\n\n1. Age ≥18 years.\n2. Confirmed diagnosis of ≥1 untreated chronic total occlusion (CTO):Defined as complete occlusion of a major coronary artery or relevant collateral (reference vessel diameter ≥2.5 mm or confirmed by two independent interventional cardiologists), with TIMI flow grade 0 in the distal segment and duration ≥3 months.Preoperatively confirmed by coronary angiography or coronary computed tomography angiography (CTCA).\n3. Willingness to undergo FAPI-PET imaging and receive PCI under imaging guidance.\n4. Ability to provide written informed consent.\n\nExclusion Criteria:\n\n1. Contraindications to antiplatelet therapy: Allergy or intolerance to aspirin, clopidogrel, or ticagrelor.\n2. Severe liver dysfunction: Liver function parameters exceeding 3× the upper limit of normal.\n3. Severe chronic kidney disease: Estimated glomerular filtration rate (eGFR) \\\u003C30 mL\u002Fmin\u002F1.73 m².\n4. Life expectancy \\\u003C1 year due to non-cardiovascular comorbidities.\n5. Pregnancy or women of childbearing potential (unless surgically sterile or using contraception).",{"count":613,"type":22},470,"2 Years","Prospective, observational, single-center cohort study\n\nHypothesis Higher myocardial FAPI uptake in CTO patients predicts a greater incidence of major adverse cardiovascular events (MACE) within 12 months after PCI. FAPI PET\u002FCT imaging is associated with plaque vulnerability features and may serve as a non-invasive marker for fibrotic activity and adverse cardiac remodeling.\n\nInclusion Criteria\n\n* Age ≥ 18 years\n* Presence of at least one untreated chronic total occlusion (CTO) lesion in a major coronary artery (diameter ≥ 2.5 mm, TIMI 0 flow for ≥ 3 months) confirmed by coronary angiography or CTCA\n* Patient eligible for PCI and undergoing FAPI PET\u002FCT imaging prior to intervention\n* Written informed consent provided\n\nExclusion Criteria\n\n* Allergy or contraindication to antiplatelet agents (aspirin, clopidogrel, or ticagrelor)\n* Severe liver dysfunction (liver enzymes \\>3× upper limit of normal)\n* Severe chronic kidney disease (eGFR \\\u003C 30 mL\u002Fmin\u002F1.73 m²)\n* Estimated life expectancy \\\u003C 1 year\n* Pregnancy or potential for pregnancy\n\nPrimary Endpoint Incidence of 1-year MACE, defined as a composite of: Cardiac death, Myocardial infarction, Stroke, Urgent revascularization\n\nSecondary Endpoints\n\n* All-Cause Mortality\n* Death from any cause within 12 months\n* Quality of Life Change: Measured by Seattle Angina Questionnaire (SAQ): changes in angina frequency, physical limitation, and treatment satisfaction\n* Repeat PCI Events: Incidence of: In-stent restenosis (ISR): ≥50% luminal loss in previously stented segment; Target lesion revascularization (TLR): at original PCI lesion; Target vessel revascularization (TVR): other sites in same vessel; De novo lesions: new lesions not previously treated\n\nSample Size Estimated 470 patients\n\nFollow-Up Duration 12 months post-PCI, One follow-up visit including clinical exam, SAQ questionnaire, imaging (PET\u002FCT, echocardiography), and laboratory testing.",[617,28],"Chronic Total Occlusion (CTO)",[619,620,621,622,623,624],"Coronary Heart Disease","Major adverse cardiovascular events (MACE)","Plaque vulnerability","Optical coherence tomography (OCT)","Fibroblast activation protein inhibitor (FAPI)","Percutaneous coronary intervention (PCI)","2025-06-16",{"date":627,"type":37},"2025-06-19",{"date":629,"type":37},"2025-04-15",{"date":631,"type":22},"2027-03-15",{"name":633,"class":44},"Lin Zhao",{"id":635,"slug":636,"hasResults":12,"nctId":637,"briefTitle":638,"officialTitle":639,"acronym":4,"eligibilityCriteria":640,"healthyVolunteers":12,"sex":18,"minAge":53,"maxAge":641,"enrollmentInfo":642,"targetDuration":4,"studyType":57,"phases":4,"briefSummary":643,"conditions":644,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":645,"lastUpdatePostDateStruct":646,"startDateStruct":648,"completionDateStruct":650,"leadSponsor":652,"locationsCount":325},"100594387","cmr-derived-quantitative-perfusion-for-prediction-of-ffr-100594387","NCT07018778","CMR-derived Quantitative Perfusion for Prediction of FFR","Quantification of Myocardial Blood Flow in Cardiovascular Magnetic Resonance for Prediction of Fractional Flow Reserve in Coronary Catheterisation","Inclusion Criteria:\n\n* clinical indication for vasodilatator CMR or invasive coronar angiography\n* capability to give informed consent\n\nExclusion Criteria:\n\n* general: non-compliance, \\\u003C18 years of age, pregnancy\n* contraindications for CMR (non-CMR compatible device, chronic kidney disease (eGFR \\\u003C30ml\u002Fmin), allergies (medications)","99 Years",{"count":220,"type":22},"Patients will undergo quantitative perfusion assessment in cardiovascular magnetic resonance imaging (dual bolus or dual sequence approach) as well as invasive coronary angiography for assessment of fractional flow reserve (FFR) including assessment of coronary flow reserve (CFR) and microcirculatory resistance (IMR).",[28],"2025-06-13",{"date":647,"type":37},"2025-06-18",{"date":649,"type":22},"2025-07-01",{"date":651,"type":22},"2026-09-30",{"name":653,"class":44},"Kerckhoff Klinik",{"id":655,"slug":656,"hasResults":12,"nctId":657,"briefTitle":658,"officialTitle":659,"acronym":660,"eligibilityCriteria":661,"healthyVolunteers":12,"sex":18,"minAge":53,"maxAge":4,"enrollmentInfo":662,"targetDuration":664,"studyType":57,"phases":4,"briefSummary":665,"conditions":666,"keywords":670,"overallStatus":91,"whyStopped":4,"lastUpdateSubmitDate":672,"lastUpdatePostDateStruct":673,"startDateStruct":675,"completionDateStruct":677,"leadSponsor":679,"locationsCount":681},"100593969","association-of-plasma-n-terminal-pro-brain-natriuretic-peptide-levels-with-the-burden-of-coronary-artery-disease-100593969","NCT07013344","Association of Plasma N-terminal Pro-Brain Natriuretic Peptide Levels With the Burden of Coronary Artery Disease","Association of Plasma N-terminal Pro-Brain Natriuretic Peptide Levels With the Burden of Coronary Artery Disease: Insights From a Real-World Cohort","BNP-CAD","Inclusion Criteria:\n\n* patient referred for elective coronary angiography due to suspected CAD.\n* NT-proBNP measurement during hospitalization\n\nExclusion Criteria:\n\n* heart failure\n* severe valvular disease\n* atrial fibrillation\n* severe chronic kidney disease (eGFR \\\u003C 30 mL\u002Fmin)\n* prior coronary artery bypass grafting\n* age over 80 years",{"count":663,"type":22},800,"1 Day","This study aim to investigate the association between plasma NT-proBNP levels and the presence, extent and severity of stenosis in patients with suspected coronary artery disease.",[28,667,276,668,669],"Chronic Coronary Total Occlusion","Stable Chronic Angina","NT-pro-BNP",[669,276,671],"Chronic Coronary Syndrome (CCS)","2025-06-05",{"date":674,"type":37},"2025-06-10",{"date":676,"type":37},"2021-09-01",{"date":678,"type":22},"2025-07-31",{"name":680,"class":44},"IRCCS Ospedale San Raffaele",2]